Novartis: Restructuring benefits visible - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Novartis: Restructuring benefits visible

Oct 31, 2001

Novartis India has announced a 6.8% growth in sales and 38% growth in PBT for 1HFY02. Subsequent to completion of the demerger of its agribusiness and amalgamation of Ciba CKD Biochem, the company has recast prior period results. The results are thus comparable on a year to year basis.

(Rs m) 2QFY01* 2QFY02 % change 1HFY01 1HFY02 % Change
Sales 1,186 1,233 3.9% 2,204 2,355 6.8%
Other Income 76 61 -18.9% 130 108 -17.0%
Expenditure 1,009 925 -8.3% 1,905 1,943 2.0%
Operating Profit (EBDIT) 177 308 73.9% 299 412 37.8%
Operating Profit Margin (%) 14.9% 25.0%   13.6% 17.5%  
Interest 29 4 -85.2% 63 29 -53.8%
Depreciation 22 20 -9.6% 43 41 -4.2%
Profit before Tax 202 345 71.1% 323 450 39.1%
Extraordinary Income - -   - -  
Tax 64 130 102.3% 103 165 60.8%
Profit after Tax/(Loss) 138 216 56.6% 221 285 29.0%
Net profit margin (%) 11.6% 17.5%   10.0% 12.1%  
No. of Shares (eoy) (m) 31.9 31.7   31.9 31.9  
Diluted Earnings per share* 17.3 27.2   13.8 17.8  
P/E (at current price) 7.4   11.3  

Though the topline figures were more or less in line with the growth in domestic pharma market, a spurt of more than 1000 basis points spurt in operating margins in 2QFY02, comes as a pleasant surprise. The improvement in operating margins was on the back of new product introductions, a sharp drop in purchase price of pharma products, and closure of its loss making ciba vision business. Though the company's top brand Voveran (an anti-inflammatory) witnessed a degrowth, sales were up due to four new products recently launched by the company.

% of sales 2QFY01 2QFY02
Raw Materials 4.9% 4.2%
Staff Costs 6.7% 7.3%
Purchase of finished goods 48.8% 40.6%

The company has also disclosed it segmental information for 1HFY02 as shown in the table below. Though on a smaller base, both consumer healthcare and animal healthcare business have grown at healthy rates. However, high marketing & sales expenses and stiff competition has impacted margins in consumer healthcare division.

Table Showing Segmentwise operating margins
1HFY02 Sales (Rs.m) Growth % Margins %*
Pharma 1970 2.7% 22.8%
Consumer Health 199 24.4% 4.5%
Animal Healthcare Business 186 40.9% 16.4%
* Profit before interest and tax

At the current market price of Rs 202, the stock trades at 12 x its annualised earnings for 1HFY02. The results of the restructuring excerise undertaken by the company is evident in current results. It seems that though would be able to maintain its margins going forward, due to its presence in niche speciality segments the topline is clearly dependent on new product introductions. However, the parent company seems uncomfortable launching new products until patent protection becomes a reality in India.


Equitymaster requests your view! Post a comment on "Novartis: Restructuring benefits visible". Click here!

  

More Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 30, 2020 12:09 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - TEVA PHARMA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS